FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

IIILJ	JIAL	ノレハし	INIUGE	COIVIIVII	33101
/achinatan	D C	20540			

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Heath-Chiozzi Margo</u>					2. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [CLDX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last)	`	irst) ERAPEUTICS,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/15/2023								X Officer (give title Other (specify below) below) SVP OF REGULATORY AFFAIRS					
53 FRONTAGE ROAD, SUITE 220				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	ON N	J	08827												iled by One iled by More		-		
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication													
							Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da						Execution Date,		Code (Ins	Transaction Disposed Of (D) Code (Instr. 5)		ities Acquir d Of (D) (Ins	ed (A) or str. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code			v	Amount	(A) o	r Price	Transac (Instr. 3	tion(s)						
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	perivative Conversion Date Execution Date, lecurity or Exercise (Month/Day/Year) if any		ate, Ti	ransaction of ode (Instr. Derivative		ve es d	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly Di or (I)	N. wnership orm: rect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
		c	Code	v	(A)	(D)	Date Exercisable		piration ate	Title	Amount or Number of Shares								
Incentive Stock Option (right to buy) ⁽¹⁾	\$36.87	06/15/2023 ⁽¹⁾			A		80,000		06/15/2024 ⁽²⁾	06	/15/2033	Common Stock	80,000	\$0	80,000		D		

Explanation of Responses:

- $1. \ Represents \ option \ granted \ by \ the \ Issuer \ pursuant \ to \ its \ 2021 \ Omnibus \ Equity \ Incentive \ Plan.$
- $2.\ 25\%\ vest\ on\ June\ 15,\ 2024\ and\ the\ remainder\ vest\ quarterly\ (in\ equal\ amounts)\ over\ the\ subsequent\ 12\ quarters.$

/s/ Sam Martin, attorney-in-fact for Margo Heath-Chiozzi 06/20/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.